New Two-Drug attack on Tough-to-Treat leukemia
NCT ID NCT06235801
Summary
This study is testing the safety and effectiveness of combining two drugs, gilteritinib and momelotinib, for adults with a specific type of acute myeloid leukemia (AML) that has a mutation called FLT3 and has come back or not responded to prior treatments. The first part of the study aims to find the safest dose of momelotinib to give with gilteritinib. The second part will look at how well the combination works to put the leukemia into remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.